Skip to content

A randomised, placebo-controlled, single blind, monocentric trial to investigate the influence of an artichoke leaf extract for the treatment of non-alcoholic fatty liver disease (NAFLD)

A randomised, placebo-controlled, single blind, monocentric trial to investigate the influence of an artichoke leaf extract for the treatment of non-alcoholic fatty liver disease (NAFLD) - SteatoChoke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00024706
Enrollment
40
Registered
2024-04-29
Start date
2022-11-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E66.0 K76.0

Interventions

Group 1: Six weeks (42 days ± 5) daily intake of an artichoke leaf extract (2600 mg). Three weeks (21 days ± 5) before surgery, additional hypocaloric, low-carbohydrate and protein-rich crash diet acc

Sponsors

Universität des Saarlandes
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Indication and decision for bariatric surgery (laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass) 2. BMI > 35 kg / m² 3. Age: 18 - 65 years 4. Ability to understand and sign the patient information and informed consent form 5. Written declaration of consent

Exclusion criteria

Exclusion criteria: 1. Alcohol consumption> 30 g / d in men,> 20 g / d in women 2. Other treatment for an existing non-alcoholic fatty liver disease 3. Allergy to artichokes and / or other cork family 4. Acute biliary diseases 5. Acute hepatitis (exception NASH) 6. Pacemaker 8. Pregnant and breastfeeding women 9. Participation in an interventional clinical study that interferes with the primary endpoint 10. Lack of patient compliance

Design outcomes

Primary

MeasureTime frame
Comparison of the degree of steatosis before and after intervention defined by the Controlled Attenuation Parameter (CAP)

Secondary

MeasureTime frame
1. Improvement of the fatty liver index after intervention compared to baseline 2. Reduction in liver size after intervention compared to baseline 3. Improvement of liver and blood values after intervention compared to basline 4. Relative weight loss (%) after intervention compared to baseline 5. Decrese in visceral fat after intervention compared to baseline 6. Analysis of the nutritional protocol 7. Surgeons assessment during surgery (fatty liver (y/n) 8. Safety and tolerability over the entire duration of the trial

Countries

Germany

Contacts

Public ContactEvelyn Marth

Universität des Saarlandes

evelyn.marth@uks.eu+49 6841 16 31018

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026